Brief: Valbiotis FY Operating Loss Widens To 5.2 Million Euros

Valbiotis SA

21/04/2020 07:08

April 21 (Reuters) - VALBIOTIS SA  ALVAL.PA :
    * EUR 8 MILLION IN CASH FLOW AS OF 31 DECEMBER 2019
    * OUTLOOK: TO LAUNCH LAST CLINICAL DEVELOPMENT STAGE OF
TOTUM-63
BY MID-2020 (PHASE II/III STUDY, REVERSE-IT)
    * OUTLOOK: GUARANTEED COLLECTION OF €6.3M IN OPERATING
INCOME OVER
THE COMING WEEKS
    * BENEFITS FROM A SOLID FINANCIAL SITUATION ENABLING IT TO
PURSUE
ITS DEVELOPMENT PLAN
    * OUTLOOK: SIGNATURE OF A GLOBAL STRATEGIC PARTNERSHIP WITH
NESTLÉ
HEALTH SCIENCE FOR THE DEVELOPMENT AND COMMERCIALIZATION OF
TOTUM-63
    * FY NET LOSS EUR 5.5 MILLION VERSUS LOSS EUR 5.0 MILLION
YEAR AGO
    * OUTLOOK: ACCELERATION OF PIPELINE'S CLINICAL DEVELOPMENT
THROUGH
LAUNCH OF THREE PHASE II STUDIES IN NEW INDICATIONS
    * FY OPERATING LOSS EUR 5.2 MILLION VERSUS LOSS EUR 4.9
MILLION
YEAR AGO
    * FY OPERATING INCOME EUR 1.9 MILLION VERSUS EUR 1.5 MILLION
YEAR
AGO

Source text for Eikon:  ID:nBwbKqKN4a 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))